Science
Paxlovid may be huge advancement for all coronaviruses: Gagandeep Kang
R. Prasad
Treatment of people infected with SARS-CoV-2 virus to prevent death and hospitalisation got a shot in the arm when Pfizer announced via press release encouraging results of an interim analysis of a phase-2/3 trial of the antiviral drug paxlovid. The drug showed 89% efficacy in preventing hospitalisation and death in certain high-risk groups when treatment was started within five days of symptom onset. The announcement comes about a month after Merck’s antiviral was found to have 50% efficacy in preventing COVID-19 death and hospitalisation.
